Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Investigation

• Publication date

  2015-11-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI82768PMID 26457733PMCID PMC4639981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gamma-sarcoglycan is required for the response of archvillin to mechanical stimulation in skeletal muscle.

  2015cited by this paper
• Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy.

  2014cited by this paper
• What Can We Learn From Clinical Trials of Exon Skipping for DMD?

  2014cited by this paper
• Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study.

  2014cited by this paper
• Dystrophin as a therapeutic biomarker: are we ignoring data from the past?

  2014cited by this paper
• Absence of γ-sarcoglycan alters the response of p70S6 kinase to mechanical perturbation in murine skeletal muscle

  2014cited by this paper
• Cellular and molecular mechanisms underlying muscular dystrophy

  2013cited by this paper
• Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy

  2012cited by this paper
• Overview on AON design.

  2012cited by this paper
• A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C.

  2012cited by this paper
• Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

  2011cited by this paper
• Systemic administration of PRO051 in Duchenne's muscular dystrophy.

  2011cited by this paper
• Restoration of γ-Sarcoglycan Localization and Mechanical Signal Transduction Are Independent in Murine Skeletal Muscle*

  2010cited by this paper
• Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

  2009cited by this paper
• Drosophila melanogaster as a model system for genetics of postnatal cardiac function.

  2008cited by this paper
• Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.

  2008cited by this paper
• Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants.

  2007cited by this paper
• Local dystrophin restoration with antisense oligonucleotide PRO051.

  2007cited by this paper
• Dystrophin, its interactions with other proteins, and implications for muscular dystrophy.

  2007cited by this paper
• Identification of functional domains in sarcoglycans essential for their interaction and plasma membrane targeting.

  2006cited by this paper
• Drosophila as a model for the identification of genes causing adult human heart disease

  2006cited by this paper
• Impact of sarcoglycan complex on mechanical signal transduction in murine skeletal muscle.

  2006cited by this paper
• Genetic background influences muscular dystrophy.

  2005cited by this paper
• Molecular and cell biology of the sarcoglycan complex

  2005cited by this paper
• Specific assembly pathway of sarcoglycans is dependent on beta‐ and delta‐sarcoglycan

  2004cited by this paper
• Nonsense-mediated mRNA decay: terminating erroneous gene expression.

  2004cited by this paper
• Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models.

  2002cited by this paper
• Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of Sarcoglycan assembly.

  2001cited by this paper
• A role for the COUP-TF-related gene seven-up in the diversification of cardioblast identities in the dorsal vessel of Drosophila.

  2001cited by this paper
• Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E.

  2000cited by this paper
• Formation of sarcoglycan complex with differentiation in cultured myocytes.

  2000cited by this paper
• Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex.

  2000cited by this paper
• Filamin 2 (Fln2)

  2000cited by this paper
• Molecular basis of muscular dystrophies

  2000cited by this paper
• Filamin 2 (FLN2): A Muscle-specific Sarcoglycan Interacting Protein

  2000cited by this paper
• The Dystrophin Complex Forms a Mechanically Strong Link between the Sarcolemma and Costameric Actin

  2000cited by this paper
• Muscle degeneration without mechanical injury in sarcoglycan deficiency.

  1999cited by this paper
• Bidirectional Signaling between Sarcoglycans and the Integrin Adhesion System in Cultured L6 Myocytes*

  1998cited by this paper
• Progressive Muscular Dystrophy in α-Sarcoglycan–deficient Mice

  1998cited by this paper
• γ-Sarcoglycan Deficiency Leads to Muscle Membrane Defects and Apoptosis Independent of Dystrophin

  1998cited by this paper
• Molecular Organization of Sarcoglycan Complex in Mouse Myotubes in Culture

  1998cited by this paper
• A founder mutation in the gamma-sarcoglycan gene of gypsies possibly predating their migration out of India.

  1996cited by this paper
• Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene.

  1996cited by this paper
• The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies.

  1996cited by this paper
• Genetic dissection of structural and functional components of synaptic plasticity. I. Fasciclin II controls synaptic stabilization and growth.

  1996cited by this paper
• Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation.

  1996cited by this paper
• Autosomal recessive limbgirdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ–sarcoglycan gene

  1996cited by this paper
• Mutations That Disrupt the Carboxyl-Terminus of γ-Sarcoglycan Cause Muscular Dystrophy

  1996cited by this paper
• Wingless signaling induces nautilus expression in the ventral mesoderm of the Drosophila embryo.

  1996cited by this paper
• Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy.

  1996cited by this paper
• β–sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex

  1995cited by this paper
• Mutations in the Dystrophin-Associated Protein γ-Sarcoglycan in Chromosome 13 Muscular Dystrophy

  1995cited by this paper
• Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy.

  1995cited by this paper
• Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy.

  1994cited by this paper
• Selective defect of sarcoglycan complex in severe childhood autosomal recessive muscular dystrophy muscle.

  1994cited by this paper
• A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin

  1993cited by this paper
• Targeted gene expression as a means of altering cell fates and generating dominant phenotypes.

  1993cited by this paper
• Dystrophin protects the sarcolemma from stresses developed during muscle contraction.

  1993cited by this paper
• Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice

  1991influential reference
• Membrane organization of the dystrophin-glycoprotein complex.

  1991cited by this paper

• Sarcospan protects against LGMD R5 via remodeling of the sarcoglycan complex composition in dystrophic mice

  2025cites this paper
• Calpainopathy (limb-girdle muscular dystrophy type R1): clinical features, diagnostic approaches, and biotechnological treatment methods

  2025cites this paper
• Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.

  2025cites this paper
• Muscular Dystrophies.

  2025cites this paper
• Recent insights into limb-girdle muscular dystrophy: Impacts, therapy, and challenges.

  2025cites this paper
• Molecular mechanisms and therapeutic strategies for neuromuscular diseases

  2024cites this paper
• Current Strategies of Muscular Dystrophy Therapeutics: An Overview.

  2023cites this paper
• Novel gamma-sarcoglycan interactors in murine muscle membranes

  2022cites this paper
• Cardiac MRI and Echocardiography for Early Diagnosis of Cardiomyopathy Among Boys With Duchenne Muscular Dystrophy: A Cross-Sectional Study

  2022cites this paper
• Inter-Species Rescue of Mutant Phenotype—The Standard for Genetic Analysis of Human Genetic Disorders in Drosophila melanogaster Model

  2022cites this paper
• Novel γ-sarcoglycan interactors in murine muscle membranes

  2022cites this paper
• Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition

  2022cites this paper
• Mesenchymal Stromal Cells and Their Secretome: New Therapeutic Perspectives for Skeletal Muscle Regeneration

  2021cites this paper
• Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases

  2021cites this paper
• Limb Girdle Muscular Dystrophy and Therapy: Current progress in Cell and Gene-based approaches.

  2020cites this paper
• A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping

  2019cites this paper
• Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies

  2019cites this paper
• Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.

  2018cites this paper
• Genetics of hypertrophic cardiomyopathy: A review of current state

  2018cites this paper
• Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing.

  2018cites this paper
• Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers.

  2018influential citation
• 226th ENMC International Workshop:: Towards validated and qualified biomarkers for therapy development for Duchenne muscular dystrophy 20-22 January 2017, Heemskerk, The Netherlands.

  2018cites this paper
• Designing Effective Antisense Oligonucleotides for Exon Skipping.

  2018cites this paper
• Molecular Therapies for Muscular Dystrophies

  2018cites this paper
• The Limb–Girdle Muscular Dystrophies: Is Treatment on the Horizon?

  2018cites this paper
• Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.

  2018cites this paper
• Limb girdle muscular dystrophies: clinical-genetical diagnostic update and prospects for therapy

  2017cites this paper
• Emerging therapeutic strategies for sarcoglycanopathy

  2017influential citation
• Treating pediatric neuromuscular disorders: The future is now

  2017cites this paper
• Pathogenesis, clinical features and diagnosis of sarcoglycanopathies

  2016cites this paper
• Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ

  2016cites this paper
• Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy – September 24–26, 2015, Ottawa, Canada

  2016cites this paper
• Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability.

  2016cites this paper
• High levels of sarcospan are well tolerated and act as a sarcolemmal stabilizer to address skeletal muscle and pulmonary dysfunction in DMD

  2016cites this paper
• Compositions et méthodes de correction de la dystrophie musculaire des ceintures de type 2c par saut d'exon

  2016cites this paper
• Antisense oligonucleotide development for the treatment of muscular dystrophies

  2016cites this paper
• Absence of γ-sarcoglycan alters the response of p70S6 kinase to mechanical perturbation in murine skeletal muscle

  2014cites this paper
• Limb-girdle muscular dystrophy

  2009cites this paper